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Available online 1 June 2016Background: Schizotypal personality disorder (SPD) is a schizophrenia-spectrum disorder characterized by odd
or bizarre behavior, strange speech, magical thinking, unusual perceptual experiences, and social anhedonia.
Schizophrenia proper has been associated with anomalies in dopaminergic neurotransmission and deﬁcits in
neurophysiologicalmarkers of self-monitoring, such as low amplitude in cognitive event-related brain potentials
(ERPs) like the error-related negativity (ERN), and the error positivity (Pe). These components occur after perfor-
mance errors, rely on adequate fronto-striatal function, and are sensitive to dopaminergic modulation. Here we
postulated that analogous to observations in schizophrenia, SPD individuals would showdeﬁcits in self-monitor-
ing, as measured by the ERN and the Pe. We also assessed the capacity of dopaminergic antagonists to reverse
these postulated deﬁcits.
Methods:We recorded the electroencephalogram (EEG) from 9 SPD individuals and 12 healthy controls in two
separate experimental sessions while they performed the Eriksen Flanker Task, a classical task recruiting behav-
ioralmonitoring. Participants received a placebo or 1mg risperidone according to a double-blind randomized de-
sign.
Results:After placebo, SPD individuals showed slower reaction times to hits, longer correction times following er-
rors and reduced ERN and Pe amplitudes.While risperidone impaired performance and decreased ERN and Pe in
the control group, it led to behavioral improvements and ERN amplitude increases in the SPD individuals.
Conclusions: These results indicate that SPD individuals show deﬁcits in self-monitoring analogous to those in
schizophrenia. These deﬁcits can be evidenced by neurophysiological measures, suggest a dopaminergic imbal-
ance, and can be reverted by dopaminergic antagonists.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
Schizotypal personality disorder
Behavioral monitoring
Neurophysiology
Error-related negativity
Dopaminergic antagonism1. Introduction
Schizotypal personality disorder (SPD) is characterized by odd or bi-
zarre behavior, strange speech, magical thinking, unusual perceptual
experiences, and social anhedonia according to the DSM-5 (Americanmacology Research Group, IIB-
a, Spain.
. This is an open access article underPsychiatric Association, 2013). From a nosological perspective, a cate-
gorical approach has conceptualized SPD as an isolated personality dis-
order that can be diagnosed when certain diagnostic criteria are met
(DSM-5). Alternatively, a dimensional approach views SPD as an atten-
uated formof schizophrenia and considers schizotypy a personality trait
that can range in a continuum from low values in health to very high
values in full-blown schizophrenia (Raine, 2006).
Individuals with high trait schizotypy show cognitive deﬁcits that
are analogous to those found in schizophrenia. High scores inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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verbal learning, spatial working memory, cognitive ﬂexibility, exec-
utive function and abstraction (Raine et al., 1995; Siever et al.,
2002; Rosell et al., 2014). This pattern of alterations suggests that
schizotypal personality and schizophrenia share a common neuro-
pathological basis involving impairment of higher cognition (Siever
et al., 2002). An unexplored aspect of cognitive function in SPD is
the potential presence of deﬁcits of self- or behavioral monitoring,
a facet of executive functioning that is crucial to differentiate be-
tween internally and externally generated actions and thoughts.
These deﬁcits are central to schizophrenia (Frith and Done, 1989;
Frith, 1995; Stephan et al., 2009) and may explain auditory halluci-
nations and delusions of control as misattributions of inner speech
and thoughts (Stephan et al., 2009).
The behavioral monitoring system has been studied extensively
using the error-related negativity or ERN. The ERN is an event-related
brain potential observed following errors in behavioral tasks
(Falkenstein et al., 1991; Gehring et al., 1993). Its generators have
been located in the frontal lobe including the anterior cingulate cortex
(ACC) (Luu and Tucker, 2001), and it is considered a correlate of the
error detection process by which the behavioral monitoring system
compares emitted responses with an internal representation of alterna-
tive options (Holroyd and Coles, 2002). The ERN is followed by the error
positivity or Pe (Falkenstein et al., 1991). Some authors have speciﬁcally
associated the Pe with the awareness of error commission
(Nieuwenhuis et al., 2001). Studies in psychiatric populations have
shown reduced ERN and Pe amplitudes in patients with schizophrenia
(Bates et al., 2002; Simmonite et al., 2012; Foti et al., 2012; Houthoofd
et al., 2013) indicating deﬁcits in the neural system involved in the gen-
eration of this component. These reductions have been proposed as an
endophenotypic marker for schizophrenia spectrum disorders
(Manoach and Agam, 2013).
Neurochemically, the ERN has been proposed to be driven by
phasic decreases in the ﬁring of mesencephalic dopaminergic neu-
rons coding reinforcement-learning signals (Holroyd and Coles,
2002). ERN amplitude is sensitive to dopaminergic antagonists. In
healthy volunteers, typical and atypical antipsychotics reduce its
amplitude (Zirnheld et al., 2004; de Bruijn et al., 2006), suggesting
that D2 receptor blockade disrupts the reinforcement-learning sig-
nals and impairs behavioral monitoring. Low ERN amplitude values
are observed in schizophrenia, and these abnormal measures nor-
malize following the administration of atypical antipsychotics such
as risperidone (Bates et al., 2004). A potential explanation for these
opposite effects is that antipsychotics reduce abnormally high dopa-
minergic tone in schizophrenia. Neuroimaging studies using 18F-
dopa have found excessive dopamine synthesis potential in this pop-
ulation (Howes et al., 2013). Dopamine levels and cognitive perfor-
mance follow an inverted U shaped function. Below or above an
optimal dopamine level, cognitive function rapidly deteriorates
(Cools and D'Esposito, 2011).
As a working hypothesis, we conceived that if SPD and schizophre-
nia share a common neurochemical basis, DA tone could also be abnor-
mally high in SPD distorting reinforcement-learning signals and
impairing behavioral monitoring. We also postulated, that deﬁcits asso-
ciated with excessive dopaminergic tone could potentially be reversed
by antipsychotic drugs with DA blocking effects.
In the present study, we assessed the behavioral monitoring sys-
tem in individuals diagnosed with SPD and a control group. Wemea-
sured the amplitude of the ERN and Pe after a placebo and 1 mg
risperidone. We postulated that individuals with SPD would show
deﬁcits in behavioral monitoring, as measured by the ERN and the
Pe, and that these deﬁcits would be reverted by risperidone. As de-
scribed in the methods section and in the Supplementary informa-
tion ﬁle, recruitment proved very difﬁcult and the ﬁnal study
sample was modest. The results of the present investigation should
consequently regarded as preliminary.2. Methods
2.1. Ethics
The study was conducted in accordance with the Declarations of
Helsinki and its updates concerning experimentation on humans, and
was approved by the hospital's ethics committee and the Spanish Min-
istry of Health. All participants gave their written informed consent
prior to participation.
2.2. Participants
Detailed information on the recruitment procedure is provided in
the Supplementary information ﬁle. The ﬁnal study sample involved 9
participants (7 women) diagnosed with schizotypal personality disor-
der and 12 healthy controls (5 women). Individuals with SPD were di-
agnosed using the Spanish version of the Structured Clinical Interview
for the DSM-IV Axis II Personality Disorders (SCID-II) (First et al.,
1999), were not seeking treatment, and had never been hospitalized
or exposed to antipsychotic medications. Scores on two questionnaires
measuring schizotypal personality traits, the Oxford-Liverpool Invento-
ry of Feelings and Experiences (O-LIFE) and the Schizotypal Personality
Questionnaire (SPQ), were also obtained (see Supplementary informa-
tion). Scores on the different subscales and factors of the O-LIFE and
SPQ questionnaires are shown in Table 1.
All participants gave their written informed consent to participate
prior to the experimental sessions.
2.3. Drugs
Participants received oral doses of 1 mg of risperidone or a placebo
(lactose capsule). This relatively low dose of risperidone was chosen
for two reasons: 1) it waswithin the dose range previously shown to re-
duce symptoms in SPD patients in a study that had used an upward ti-
tration from 0.25 to 2 mg/day (Koenigsberg et al., 2003); and 2) it was
low enough to prevent observations in healthy volunteers from being
confounded by excessive somnolence.
2.4. Experimental design
The study was carried out according to a double-blind randomized
cross-over design. SPD and controls participated in two different exper-
imental sessions in which they were tested after receiving the placebo
or the 1 mg oral dose of risperidone. Experimental days were one
week apart. Upon arrival in the laboratory, electrodes were applied to
the scalp andmedicationwas given. During each recording session, vol-
unteers remained in a quiet room andwere asked to stay alert through-
out the experiment. The behavioral task and electroencephalography
recording (EEG) were conducted 2 h after drug administration when
the peak risperidone plasma levels were expected.
2.5. Behavioral task and EEG recording
The electroencephalogram (EEG) was recorded continuously from
the scalp while participants performed the Eriksen Flanker Task
(Eriksen and Eriksen, 1974), a classical task recruiting behavioral mon-
itoring. A series of behavioral parameters and event-related brain po-
tentials (ERPs) were derived from the task. A detailed description of
the task, recording procedure, signal processing, and component quan-
tiﬁcation is provided in the Supplementary information ﬁle.
2.6. Statistical analyses
Sociodemographic (age and sex), behavioral and ERP data are pre-
sented in summaries as means and standard deviation (SD). Sample
Table 1
Scores on the different subscales and factors of the Oxford-Liverpool Inventory of Feelings and Experiences (O-LIFE) and the Schizotypal Personality Questionnaire (SPQ) for the patient
sample and the controls. Data expressed as mean (standard deviation).
Instrument Between groups comparison
Controls
n = 12
Patients
n = 9
t-value
df(19)
p value Cohen's d
O-LIFE
Total score 22.33 (12.05) 61.67 (9.41) −8.10 b0.001 3.64
Unusual experiences 6.08 (4.89) 22.33 (3.74) −8.30 b0.001 3.74
Cognitive disorganization 5.83 (4.69) 17.89 (3.79) −6.31 b0.001 2.83
Introvertive anhedonia 3.67 (2.43) 10.67 (4.72) −4.44 b0.001 1.86
SPQ
Total score 14.00 (7.79) 44.67 (6.75) −9.44 b0.001 4.21
Ideas of reference 1.92 (1.73) 4.22 (1.56) −3.146 0.005 1.40
Odd beliefs/magical thinking 1.42 (1.88) 4.67 (1.66) −4.12 0.001 1.83
Unusual perceptual experiences 0.92 (1.17) 5.78 (2.05) −6.90 b0.001 2.05
Paranoid ideation 1.50 (1.45) 3.67 (1.87) −2.99 0.007 1.87
Social anxiety 1.75 (1.87) 5.33 (2.65) −3.65 0.002 2.65
No close friends 1.92 (1.31) 3.78 (1.72) −2.82 0.011 1.22
Constricted affect 1.17 (1.12) 3.67 (1.50) −4.39 b0.001 1.89
Eccentric/odd behavior 0.58 (0.99) 4.89 (2.62) −5.25 b0.001 2.62
Odd speech 1.33 (0.89) 5.00 (1.50) −7.02 b0.001 2.98
Cognitive-perceptual factor 5.75 (4.88) 18.33 (3.78) −6.41 b0.001 2.88
Interpersonal factor 6.33 (3.85) 16.44 (4.36) −5.63 b0.001 2.46
Disorganized factor 1.92 (1.31) 9.89 (3.56) −7.20 b0.001 2.97
772 M. Rabella et al. / NeuroImage: Clinical 11 (2016) 770–779matching variables were analyzed using independent samples,
Student's t-tests and the χ2 test (sex distribution).
The statistical analysis of the behavioral and ERP data was designed
to evidence: 1) trait group differences between SPD individuals and
controls; and 2) state differences associated with risperidone
administration.
To test for trait differences between groups, behavioral and ERP data
in the placebo condition were compared between groups using inde-
pendent samples t-tests. In the case of the ERP data, the statistical com-
parisons were conducted at the three midline electrodes (Fz, Cz, Pz).
To test for differences in the pharmacological intervention, behav-
ioral and ERP data were analyzed using two-way ANOVAs with the
within-subjects Treatment factor (placebo vs. risperidone) and the be-
tween-subjects factor Group (controls vs. SPD individuals). In the spe-
ciﬁc case of the ERP data, to simplify the interpretation of the two-
way ANOVA and to avoid triple interactions, separate analyses were
conducted at each of three midline electrodes (Fz, Cz, Pz). The contrast
of interest was the interaction Treatment by Group. A signiﬁcant inter-
action indicated the differential modulation of a behavioral or ERP var-
iable by the risperidone treatment.
To test for compatibility effects on the P2 and P3 components of the
stimulus-locked averages and their modulation by risperidone, a three-
way ANOVA was conducted with factor Compatibility (compatible vs.
incompatible stimuli), Group (controls vs. SPD individuals) and Treat-
ment (placebo vs. risperidone). Again, to simplify interpretation of re-
sults, separate analyses were conducted at each of three midline
electrodes (Fz, Cz, Pz). Two were the contrasts of interest in this analy-
sis: First, the Compatibility by Group interaction. It indicated a differen-
tial processing of conﬂict-eliciting stimuli (the incompatible stimuli)
between groups. Second, the Treatment by Compatibility by Group in-
teraction. It indicated a differential impact of risperidone on one sub-
group and stimulus type.
Statistical analyses were conducted using the SPSS software. Addi-
tionally, effect size (Cohen's d and Cohen's f) was calculated using the
G*Power software (Faul et al., 2007). Using G*Power we estimated
that with 9 SPD patients and 12 controls we had 80% power to detect
an effect of d = 1.14 in the independent samples t-tests, and an effect
of f = 0.32 in the within-between interaction of the ANOVA. For all
ANOVA results, p values after Greenhouse-Geisser correction are
given. Differences were considered statistically signiﬁcant for p b 0.05.3. Results
3.1. Behavior
Summary behavioral data from the Eriksen Flanker task and the re-
sults of the statistical analyses are shown in Table 2. The analysis of be-
havior in the absence of pharmacological treatment showed trait
differences between the two participant groups. Under placebo, perfor-
mance was worse in the SPD individuals than in the control group. Re-
action times to correctly-responded stimuli were signiﬁcantly slower
for SPD individuals than for controls, without this leading to greater ac-
curacy (no statistical differences in the % of correct and erroneous re-
sponses). The time taken to correct choice errors was also greater in
the SPD than in the control group. The mean percentage of erroneous
responses that were subsequently corrected was also lower for SPD in-
dividuals, but the statistical comparison only showed a trend. No other
signiﬁcant differences were found.
The analysis of the impact of the pharmacological intervention is
shown in the two-way ANOVA with Group and Treatment as factors.
This analysis showed a signiﬁcant Treatment by Group interaction for
the time taken to correct erroneously responded stimuli. Risperidone
administration modulated this variable differentially between groups.
While correction time increased in the control group under risperidone,
the drug decreased it in the SPD group.
3.2. Response-locked ERPs
Response-locked averages associatedwith correct and erroneous re-
sponses for SPD individuals and controls are shown in Fig. 1. Mean am-
plitude values are shown in Table 3. In the averages associated with
erroneous responses a negative-going deﬂection, the ERN, was ob-
served in the ERP. The ERN can be seen to rise immediately following
the choice errors, peaking within the next 100 ms. This component
was followed by a positive deﬂection, the Pe.
To test for trait differences between groups in the amplitude of the
ERN and Pe we performed between-subjects comparisons of the peak
values of these components at the three midline electrodes (Fz, Cz, Pz)
following placebo. Mean peak values indicated larger (i.e., more nega-
tive) ERN amplitudes in the controls than in the SPD group. The statisti-
cal analysis showed that these differences were statistically signiﬁcant
Table 2
Behavior in the Eriksen Flanker Task, expressed asmean (standard deviation). RT= reaction time. Post-error slowing: RT increase in correct trials that follow an error trial relative to cor-
rect trials that follow another correct trial. RT incompatibility: reaction time increase in correctly-responded incompatible (HHSHH and SSHSS) relative to correctly-responded compatible
trials (HHHHH and SSSSS). Error incompatibility: increase in the number of committed errors in incompatible relative to compatible trials. d: Cohen's d; f: Cohen's f.
Placebo Between groups comparison Risperidone Treatment × group interaction
Controls Patients t-value p value d Controls Patients F(1,19) p value f
Total responses 1126 (96) 989 (262) 1.48 0.171 0.69 1068 (114) 1015 (197) 1.42 0.248 0.27
Omitted responses 47 (50) 191 (247) −1.73 0.120 0.81 93 (77) 163 (187) 1.78 0.197 0.31
% correct responses 78.8 (12.3) 79.2 (9.7) −0.07 0.944 0.03 78.3 (10.7) 81.2 (5.1) 0.59 0.452 0.18
% errors 21.2 (12.3) 20.8 (9.7) 0.07 0.944 0.04 21.7 (10.7) 18.8 (5.1) 0.59 0.452 0.18
% corrected errors 88.8 (10.3) 69.1 (29.7) 1.91 0.087 0.89 86.2 (10.9) 66.4 (29.0) 0.00 0.991 0.01
RT correct responses 339 (74) 419 (73) −2.48 0.023⁎ 1.09 360 (73) 435 (85) 0.11 0.745 0.07
RT corrected errors 185 (52) 320 (98) −3.77 0.003⁎ 1.72 213 (71) 313 (88) 6.91 0.017⁎ 0.60
Post-error slowing 17 (33) 27 (54) −0.53 0.660 0.22 13 (28) 22 (56) 0.01 0.933 0.02
RT incompatibility 19 (11) 26 (13) −1.47 0.159 0.58 23 (22) 27 (11) 0.21 0.649 0.11
Error incompatibility 9.0 (5.4) 7.6 (5.3) 0.61 0.545 0.26 10.4 (7.8) 10.2 (3.4) 0.29 0.599 0.12
⁎ p b 0.05.
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at Cz and Pz. The statistical comparison was signiﬁcant at Pz.
To test for differential drug effects we conducted the two-way
ANOVA with Treatment and Group as factors at each of the three mid-
line electrodes. As shown in Table 3, we found signiﬁcant Treatment
by Group interactions for the ERN at Fz and Cz. While risperidone de-
creased ERN amplitude in the controls, it led to increases in the SPD
group. No main effects of Treatment or Group were observed at any of
the three leads in the ANOVA. Regarding the Pe, nomain effects or inter-
actions were observed in the two-way ANOVA for this component.
Unexpectedly, the visual inspection of the response-locked correct
responses showed a rudimentary negativity immediately following
the emission of the correct response. This wave, which is known as
the correct-related negativity or CRN, was seen in the controls and the
SPD individuals at Fz and more markedly in the SPD group at Cz. To
look for trait differences and treatment effects, we analyzed the CRN
measuring the peak positive value in the 0–100 ms time window in
the individual averages of the correct responses and using the same sta-
tistical approach employed for the ERN and the Pe.
Mean (SD) CRN values were more negative in the SPD than in the
control group, but no statistically signiﬁcant differences were found:
Fz: SPD −0.19 (2.59) μV, controls 0.22 (4.17), t(19) = 0.26, n.s.; Cz
SPD −0.61 (2.84) μV, controls 0.93 (5.21), t(19) = 0.79, n.s.; Pz SPD
−0.49 (2.15) μV, controls 0.53 (3.93), t(19) = 0.70, n.s. The two-way
ANOVAwith Treatment andGroup as factors showed a signiﬁcant inter-
action at Cz [F(1,19) = 4.82, p = 0.041], reﬂecting a CRN enhancing ef-
fect of risperidone in the SPD group only.
3.3. Stimulus-locked ERPs
Stimulus-locked averages after correct responses for compatible and
incompatible trials combined are shown for each participant group in
Fig. 2, and mean amplitude values in Table 4. The most prominent fea-
tures observed in the averages are two centro-parietal positive-going
deﬂections, the P2 peaking between 100 and 200 ms and the P300
peaking between 200 and 300 ms post-stimulus.
The between-subjects comparison of the P2 peak amplitudes
showed signiﬁcantly smaller values in the SPD group after placebo.
These smaller trait values were normalized by risperidone. The two-
way ANOVA found a signiﬁcant Treatment by Group interaction at Pz
and a marginally signiﬁcant one at Cz. While the drug did not induce
any changes in P2 amplitude in the controls, it increased P2 amplitude
in the patient group.
The between-subjects comparison of the P300 variables showed sig-
niﬁcant differences in latency at Cz and Pz, with values being larger in
the patient group. Although the ERP averages showed a smaller P300
amplitude also in the SPD group, this trait differencewas not signiﬁcant.
The visual inspection of the waves showed that following risperidone,amplitude and latency were not modiﬁed in the control group. On the
other hand, the P300 appeared larger and peaking later in the SPD
group. However, the two-way ANOVA did not ﬁnd any signiﬁcant
main effect of Treatment or a Treatment by Group interaction at any
of the three electrodes.
Fig. 3 shows the averages of the correctly-responded stimulus-
locked averages separately for compatible and incompatible stimuli.
As shown in the ﬁgure, a compatibility effect was observable in the
P300 for the SPD group only. This compatibility effect consisted in larger
peak amplitude values after incongruent (SSHSS andHHSHH) than con-
gruent (SSSSS and HHHHH) stimuli. Also, the visual inspection of the
traces suggested that risperidone did not modify the amplitude values
in the control group, but increased them in the SPD individuals, espe-
cially in the incompatible condition. Mean peak amplitude values for
each group, condition and treatment are shown in Table 5.
To analyze the compatibility effect, a three-way ANOVA was con-
ducted with Treatment (placebo vs. risperidone) and Compatibility
(compatible vs. incompatible) as within-subjects factors and Group
(controls vs. SPD) as between-subjects factor at each of the three mid-
line electrodes. The results showed a signiﬁcant interaction Compatibil-
ity by Group at Cz and Pz, corroborating the selectivity of the
compatibility effect for the SPD group. Marginally signiﬁcant triple in-
teractions Treatment by Compatibility by Group were observed at Fz
and Cz. These interactions supported as well a selective effect of risper-
idone on the incongruent trials in the SPD patient group.3.4. Comparative analysis of effect size and power
The main ﬁnding of the present study is the reduced amplitude of
the ERN in SPD patients and its enhancement by the antipsychotic
drug risperidone. Given the small patient sample recruited, we wished
to compare the size of these effectswith those of analogous studies pub-
lished in the literature. To do this we used Cohen's d and Cohen's f. As
indicated in the methods section, we had calculated that with our par-
ticipant sample (9 patients and12 controls)wehad 80%power to detect
an effect of d= 1.14 in the independent samples t-tests (pre-treatment
between-groups comparisons), and an effect of f = 0.32 in the within-
between interaction of the ANOVA, i.e., in the Treatment byGroup inter-
action. Size of the effect in studies by other research groups were calcu-
lated post-hoc using the means and standard deviations published in
four different papers. These studies assessed ERN amplitude in individ-
uals with high trait schizotypy (Kim et al., 2015) and in schizophrenia
patients (Bates et al., 2004; Morris et al., 2011; Simmonite et al., 2012).
Summary data are presented in Table 6. As shown therein, the effect
size of the pre-drug comparison of ERN amplitude between controls and
SPD patients in our study was within the range of previously published
values (0.46–2.37).
Fig. 1. Response-locked ERPs associated with the Eriksen Flanker task. Grand-mean averages at Fz, Cz and Pz for erroneously- and correctly-responded stimuli. The left panels show
averages for the control group and the right panels for the SPD group. The negative-going deﬂection following a choice error is the ERN, and the subsequent positivity, the Pe. Note the
reduced amplitude of the ERN and Pe waves following placebo (black solid lines) in the SPD group as compared to the healthy controls group. After risperidone (grey lines), the ERN is
reduced in the control group and increased in the SPD group. The grand-averages have been band-pass ﬁltered (2–8 Hz) for display purposes. The topographical map shows the peak
activity of the ERN expressed as the difference wave between error - correct responses. Relative scaling was used. Minimum and maximum values:−6/+4 μV.
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Here we showed that compared to controls, SPD individuals show
abnormally small amplitudes of the ERN and the Pe, twoneurophysiological correlates of behavioral monitoring. These neuro-
physiological abnormalities were paralleled by worse performance in
the Eriksen Flanker task. Individuals with SPD were slower in their re-
sponse to the targets and their corrective actions after choice errors.
Table 3
Peak amplitude values for the ERP components obtained from the response-locked averages, i.e., the ERN and the Pe. Peak amplitudes are expressed in microvolts and latencies in milli-
seconds. d: Cohen's d; f: Cohen's f.
Electrode Placebo Between groups comparison Risperidone Treatment × group interaction
Controls Patients t-value p value d Controls Patients F(1,19) p value f
Response-locked ERP amplitude values after incorrect responses (ERN)
Fz −4.78 (2.38) −2.93 (2.50) −1.73 0.100 0.76 −3.56 (2.21) −4.04 (2.38) 6.49 0.020⁎ 0.59
Cz −6.75 (3.08) −3.38 (2.42) −2.71 0.014⁎ 1.22 −4.77 (2.90) −5.26 (3.48) 11.62 0.003⁎ 0.78
Pz −2.51 (2.19) −1.20 (1.50) −1.54 0.141 0.70 −1.98 (1.15) −2.08 (1.75) 2.61 0.122 0.37
Response-locked ERP amplitude values after incorrect responses (Pe)
Fz 4.80 (2.96) 5.33 (3.83) −0.36 0.726 0.15 5.49 (2.44) 5.27 (2.75) 0.33 0.571 0.13
Cz 9.10 (4.58) 7.03 (4.73) 1.01 0.324 0.44 9.47 (4.08) 8.40 (4.38) 0.46 0.505 0.16
Pz 4.71 (2.59) 2.64 (1.61) 2.11 0.049⁎ 0.96 5.47 (2.89) 4.14 (3.21) 0.36 0.553 0.14
⁎ p b 0.05.
775M. Rabella et al. / NeuroImage: Clinical 11 (2016) 770–779Importantly, ERN amplitude deﬁcits and some aspects of behavior were
reversed in the SPD groupwith the administration of risperidone.While
risperidone reduced ERN amplitude and worsened performance in the
healthy controls, it improved correction time and increased ERN ampli-
tude in the SPD group.Fig. 2. Stimulus-locked ERPs associatedwith the Eriksen ﬂanker task. Grand-mean averages at C
averages. The P200 peaks around 200ms, and the P300 between 300–500ms after stimulus pre
The topographical map shows the peak activity of the P300. Relative scaling was used. MinimuThe analysis of the stimulus-locked averages also showed alterations
in stimulus perception and categorization in the SPD group. The ampli-
tude of the P2, an exogenous component associatedwith stimulus iden-
tiﬁcation (Crowley and Colrain, 2004), was reduced in the SPD sample.
SPD individuals also showed larger P300 latencies in the placeboz and Pz for correctly-responded stimuli. Two positive-going deﬂections can be seen in the
sentation. The grand-averages have been band-pass ﬁltered (2–8 Hz) for display purposes.
m and maximum values:−1/+9 μV.
776 M. Rabella et al. / NeuroImage: Clinical 11 (2016) 770–779condition, suggesting a slowed stimulus categorization in this group. In-
terestingly, the conﬂict-inducing incompatible stimuli produced an in-
crease in P300 amplitude in the patient group only. While previous
studies have usually found increased P300 latencies and blunted ampli-
tudes in schizophrenia patients (Allen et al., 2009), to our knowledge
this compatibility effect has not been described previously. This ﬁnding
can be interpreted as the patients having experienced an exaggerated
increase in processing demands when target letter and ﬂankers di-
verged (Rusnáková et al., 2011). Risperidone was able to normalize
the amplitude values of the P2 in the patient group, both in compatible
and incompatible trials. It also selectively increased P300 amplitude in
the incompatible trials, potentially reﬂecting a beneﬁcial effect of the
drug in networks processing conﬂict. Importantly, no drug effects
were observed on the P2 or P300 amplitudes in the healthy volunteers
that could suggest a general unspeciﬁc reduction in general vigilance in-
duced by the risperidone dose administered.
The ﬁndings discussed above suggest that individuals with SPD
show deﬁcits in behavioral monitoring, but also in stimulus processing.
These results extend previous ﬁndings that showed neurophysiological
anomalies in SPD. A prior study had identiﬁed alterations in the mis-
match negativity in this population (Hong et al., 2012), suggesting im-
pairment in automatic detection of deviant characteristics of stimuli.
In another study, the authors found decreased phase-locking following
auditory stimulus presentation (Shin et al., 2010). In line with the self-
monitoring deﬁcits found in our study, several research groups have
found that SPD patients show reduced N400 amplitudes, indicating
poor semantic monitoring in this population (Debruille et al., 2007;
Wang et al., 2013).
As hypothesized, ERN and Pe amplitude were reduced in agreement
with previous ﬁndings in patients with schizophrenia (Mathalon et al.,
2002;Morris et al., 2011; Simmonite et al., 2012; Foti et al., 2012). Inter-
estingly, the size of the effect of ERN amplitude differences between
participants found in our study at the Fz electrode (d = 0.76) is higher
than that reported by Kim and coworkers in their sample of healthy in-
dividuals scoring high on schizotypy (Fz: 0.46), but lower than the
values reported for schizophrenia patients in several studies (Fz: 1.17,
Simmonite et al., 2012; FCz: 0.84, Morris et al., 2011; Fz: 1.76, Bates et
al., 2004). These differences suggest an increasing impairment of self-
monitoring from health to high trait schizotypy/SPD and to full-blown
schizophrenia.
In the only other study that we know of assessing the effects of anti-
psychotics on the ERNof patients, Bates and colleagues showed lowERN
amplitude after commission errors in schizophrenia patients
performing a go-no go task. Despite the small sample recruited by
these authors (9 patients and 9 controls), they also showed that phar-
macological treatment was able to increase ERN amplitude, reversing
the initially observed deﬁcits after six weeks of treatment (Bates et al.,
2004). These results suggest that an abnormally small ERN is a deﬁcitTable 4
Amplitude and latency values for the ERP components obtained from the stimulus-locked avera
milliseconds. d: Cohen's d; f: Cohen's f.
Electrode Placebo Between groups comparison
Controls Patients t-value p value d
Stimulus locked ERP amplitude after correct responses (P2)
Fz_amplitude 4.9 (3.2) 3.5 (2.7) 1.01 0.325 0
Cz_amplitude 5.7 (3.5) 3.7 (3.1) 1.37 0.188 0
Pz_amplitude 5.2 (2.7) 2.6 (2.3) 2.36 0.029⁎ 1
Stimulus locked ERP amplitude after correct responses (P300)
Fz_latency 377 (31) 417 (56) −1.95 0.075 0
Cz_latency 371 (24) 416 (54) −2.37 0.038⁎ 1
Pz_latency 362 (30) 419 (56) −2.76 0.018⁎ 1
Fz_amplitude 6.4 (5.3) 5.3 (2.7) 0.68 0.504 0
Cz_amplitude 10.8 (5.9) 7.4 (4.2) 1.45 0.164 0
Pz_amplitude 9.3 (4.7) 6.1 (3.3) 1.73 0.101 0
⁎ p ≤ 0.05.present in both disorders. The idea of a trait alteration in the neural net-
works subserving this neurophysiological marker in schizophrenia
spectrum disorders is further supported by the fact that our SPD sample
was free of the usual confounds present in studies on schizophrenia.
Such confounds include disease progression, the acute effects of anti-
psychotic medication and neural adaptations to pharmacological
treatment.
Our results add to previous studies in schizophrenia showing deﬁcits
of self-monitoring, deﬁned as the ability to control self-initiated behav-
ior and cognitive processes. Deﬁcits in the correct attribution of actions
and thought processes to internal or external sourcesmay be at the core
of schizophrenia (Frith and Done, 1989; Frith, 1995; Stephan et al.,
2009) in the absence of attentional deﬁcits (Turken et al., 2003). Re-
duced functional connectivity between areas mediating an action
(speech generation) and those mediating certain aspects of that action
(speech perception) has also been described (Ford et al., 2002). Defec-
tive self-monitoringwould explain the attribution of inner speech to ex-
ternal sources in auditory hallucinations, and phenomena such as
thought insertion or control (Stephan et al., 2009).
It is noteworthy that risperidone administration led to opposite ef-
fects on the ERN in the SPD and control populations. This was observed
both at the neurophysiological and behavioral levels. Signiﬁcant
drug × group interactions were seen for ERN amplitude and for the
time taken to correct a choice error.While risperidone reduced ERN am-
plitude and increased correction time in the healthy controls, it led to
the reverse effects in the SPD patients. Prior studies involving antipsy-
chotic drug administration to healthy subjects have found an inhibitory
effect of both the typical and atypical drugs on this ERP, such as haloper-
idol (Zirnheld et al., 2004; de Bruijn et al., 2006) and olanzapine (de
Bruijn et al., 2006). In line with the paradoxical effect observed in our
SPD sample, Bates and colleagues found that whereas the ERN was re-
duced in schizophrenia patients in the early stages of an acute episode,
it's amplitude increased following pharmacological treatment with
atypical antipsychotics (Bates et al., 2004). Althoughnoprevious studies
exist on the effects of antipsychotics on the ERN in SPD, Koenigsberg and
colleagues have shown that a low dose regime of risperidone is effective
at reducing positive and negative symptoms in this population
(Koenigsberg et al., 2003).
Our ﬁndings suggest a normalizing effect of risperidone on neuro-
physiological and behavioral deﬁcits in the disease. The ERN has been
associated with a neural network involving the ACC (Dehaene et al.,
1994; Ridderinkhof et al., 2004; Doñamayor et al., 2012), the substantia
nigra/VTA (Dehaene et al., 1994), the dorsolateral prefrontal cortex
(Gehring and Knight, 2000) and the basal ganglia (Falkenstein et al.,
2001). Holroyd and Coles have proposed a model in which mesence-
phalic dopamine pathways code a reinforcement-learning signal that
is conveyed to the ACC. According to this model, when an error is com-
mitted, decreases in phasic dopamine release disinhibit ACC neuronsges, i.e., the P2 and the P300. Peak amplitudes are expressed inmicrovolts and latencies in
Risperidone Treatment × group interaction
Controls Patients F(1,19) p value f
.47 5.5 (3.7) 5.1 (2.5) 0.74 0.401 0.20
.60 6.0 (3.6) 5.7 (3.08) 4.39 0.050⁎ 0.48
.04 5.3 (2.6) 5.1 (2.5) 22.2 b0.001⁎ 1.08
.88 393 (39) 428 (63) 0.13 0.720 0.08
.08 383 (31) 432 (50.1) 0.04 0.837 0.04
.27 370 (38) 432 (53) 0.12 0.733 0.08
.26 7.0 (4.3) 6.5 (3.3) 0.11 0.746 0.08
.66 10.7 (5.1) 9.7 (4.9) 1.91 0.183 0.32
.79 9.1 (5.1) 8.7 (3.5) 2.97 0.101 0.40
Fig. 3. Stimulus-locked averages at Cz and Pz, shown separately for compatible and incompatible correctly-responded stimuli. Note the smaller P200 in the patient group after placebo, and
the increase in amplitude following risperidone. Note also the compatibility effect on the P300 after placebo, which is observed in the patient group only. Risperidone showed a trend to
selectively enhance P300 amplitude in the SPD group only and speciﬁcally for the incompatible trials (Treatment × Compatibility × Group interaction: Fz: F(1,19)= 3.73, p = 0.069; Cz:
F(1,19) = 4.29, p = 0.052). The grand-averages have been band-pass ﬁltered (2–8 Hz) for display purposes.
777M. Rabella et al. / NeuroImage: Clinical 11 (2016) 770–779that generate the ERN (Holroyd and Coles, 2002). While some reports
have suggested a role of other neuromodulatory systems (Riba et al.,
2005), the available pharmacological evidence suggests a heavy inﬂu-
ence of the dopaminergic system. Within this framework, the present
ﬁndings of a reduced ERN and its enhancement by risperidone point
at a dysregulation of dopaminergic neurotransmission in the meso-
cortico-striatal network. In support of this possibility, a recent neuroim-
aging study has found that improvement in psychotic symptoms after
risperidone is associated with increased functional connectivity be-
tween the striatum and the anterior cingulate and dorsolateral prefron-
tal cortex (Sarpal et al., 2015).
Dopaminergic dysregulation in SPD patients is also supported by
post-mortem and neuroimaging studies showing elevated dopaminer-
gic activity in schizophrenia spectrum disorders. Patients with schizo-
phrenia show elevated midbrain dopamine synthesis capacity and
increased 18F-DOPA uptake in the substantia nigra and the striatum
(Howes et al., 2013), ﬁndings that extend to individuals showing pro-
dromal symptoms (Howes et al., 2009). 18F-DOPA uptake in theTable 5
Amplitude values for the P300 shown separately for compatible and incompatible trials. Peak a
Comp: compatible; Incomp: incompatible; Compat: compatibility; Treat: treatment; degrees o
Controls SPD patients
Placebo Risperidone Placebo
Electrode Comp Incomp Comp Incomp Comp Incom
Fz 6.3 (3.6) 6.8 (4.6) 7.5 (4.7) 6.9 (4.2) 5.0 (2.6) 5.5 (2.
Cz 10.6 (5.5) 11.1 (6.0) 11.2 (6.0) 10.9 (5.0) 6.9 (4.1) 7.7 (4.
Pz 9.4 (4.7) 10.2 (4.8) 9.6 (5.6) 9.3 (4.8) 5.8 (3.4) 6.7 (3.
⁎ p b 0.05.striatum is increased in subjects at ultra-high risk for psychosis
(Egerton et al., 2013). High schizotypal personality traits have also
been associated with abnormalities in dopaminergic neurotransmis-
sion. Individuals scoring high in the SPQ questionnaire show exacerbat-
ed dopamine release in the striatum following amphetamine challenge
(Woodward et al., 2011). Dopamine release levels in diagnosed SPD pa-
tients are higher than in controls, and analogous to those in remitted
schizophrenia patients (Abi-Dargham et al., 2004).
Additional evidence of modiﬁcations in dopaminergic neurotrans-
mission include decreased D2 receptor binding in the ACC (Suhara et
al., 2002) and the substantia nigra/ventral tegmental area (Kessler et
al., 2009). Schizotypy as a trait has been associated with alterations in
D2 receptor availability in the striatum (Mohr and Ettinger, 2014).
Also, analogously to observations in schizophrenia, increased dopamine
release following amphetamine challenge has been shown in SPD pa-
tients using SPECT (Abi-Dargham et al., 2004). In healthy volunteers,
dopamine release after amphetamine challenge correlates positively
with schizotypal traits (Woodward et al., 2011).mplitudes are expressed in microvolts.
f freedom (1,19); d: Cohen's d; f: Cohen's f; p: p value.
Three-way ANOVA
Risperidone Compat × group Treat × Compat ×
group
p Comp Incomp F p d F p f
4) 6.0 (2.4) 7.4 (3.8) 2.92 0.104 0.39 3.73 0.069 0.44
2) 8.8 (3.1) 11.4 (5.8) 5.03 0.037⁎ 0.51 4.29 0.052 0.47
3) 8.3 (2.5) 10.1 (4.6) 5.40 0.031⁎ 0.53 2.76 0.113 0.38
Table 6
Comparison table showing effect sizes of ERNdifferences betweenhealthy controls, SPD patients, high schizotypal trait individuals, and schizophrenia patients across studies. d: Cohen's d;
HC: healthy controls; SPD: schizotypal personality disorder patients; HTS: high schizotypal trait individuals; SCHZ: schizophrenia patients. The “Controls”, “Patients” and “Amplitude in
Patients” columns show mean (SD) amplitude values for each subgroup. For comparison purposes, in the present study, effect size (Cohen's d) in the between-groups comparison was
0.76 at Fz and 1.22 at Cz.
Study Sample Electrode Between groups comparison Treatment effect⁎
Controls Patients d Amplitude in patients d
Kim et al. (2015)
n1 = 20
n2 = 17
HC vs. HTS Fz −3.76 (3.41) −2.48 (1.91) 0.46 – –
Cz −5.92 (2.5) −3.25 (2.41) 1.09 – –
Simmonite et al. (2012)
n1 = 35
n2 = 29
HC vs. SCHZ Fz −6.67 (4.89) −1.25 (4.34) 1.17 – –
Cz −4.7 (4.59) −0.29 (3.93) 1.03 – –
Morris et al. (2011)
n1 = 21
n2 = 15
HC vs. SCHZ FCz −11.46 (10.26) −4.66 (4.96) 0.84 – –
Bates et al. (2004)
n1 = 9
n2 = 9
HC vs. SCHZ Fz −9.86 (2.69) −4.34 (3.54) 1.76 −7.77 (3.72) 0.94
Cz −12.5 (3.35) −4.27 (3.6) 2.37 −8.46 (3.90) 1.11
⁎ Treatment effect calculated only for patients, using paired samples Student's t-test.
778 M. Rabella et al. / NeuroImage: Clinical 11 (2016) 770–779The differential modulation by risperidone found here may be ex-
plained by differences in dopaminergic tone between controls and
SPD individuals and the inverted-U-function between dopamine levels
and performance proposed by Cools and D'Esposito (Cools and
D'Esposito, 2011). In the controls, D2 receptor blockade leads to
lower-than-normal dopamine-D2 receptor interactions and thus to
sub-optimal dopaminergic tone in the meso-cortico-striatal network
that gives rise to the ERN and regulates behavioral monitoring. In the
patient group, an abnormally enhanced dopaminergic tone may have
been tuned-down by risperidone improving cognitive function and in-
creasing the ERN. Importantly, this beneﬁcial effect was observed with
a low dose of risperidone that must have led only to partial D2 receptor
occupancy (Kapur et al., 1999). Analogous baseline-dependent effects
on performance have been observed in healthy volunteers administered
the dopaminergic agonist bromocriptine. The study found that individ-
uals with low dopamine synthesis capacity had their performance im-
proved by the drug in a reversal learning task, while subjects with
high dopamine synthesis capacity were impaired by the drug (Cools et
al., 2009).
The relevance of our present ﬁndings goes beyond the study of SPD.
This disorder is a useful target for the deﬁnition of endophenotypes in
schizophrenia spectrum disorders. Research into SPD allows the assess-
ment of biological and cognitive markers without the confounding fac-
tors of a major disorder, such as neural changes associated with the
natural course of the disease and neural adaptations secondary to
chronic pharmacological treatment (Raine et al., 1995). Our ﬁndings
also support the use of the ERN as a correlate of behavioral monitoring
in these populations. Recently, Manoach and Agam proposed the use
of neurophysiological correlates of errors as endophenotypes in psychi-
atric disorders and as surrogate markers of response to treatment
(Manoach and Agam, 2013). A blunted ERN is also present in other psy-
chotic disorders where self-monitoring and insight are compromised
(Foti et al., 2012). Simmonite and colleagues have shown reduced
ERNs in symptom-free schizophrenia patients' siblings (Simmonite et
al., 2012). Their sample showed ERNs of intermediate amplitude, i.e.
lower than those of healthy controls, but higher than those of patients.
Importantly, while in our study the SPD individuals shared symptoms
analogous to the schizophrenia prodrome, the unaffected siblings in
the study by Simmonite and coworkers did not show any prodromal
symptoms of schizophrenia. Nevertheless, their ERNwas reduced com-
pared to healthy controls. Contrary to the present observations, the ERN
is increased in obsessive-compulsive disorder patients and their unaf-
fected ﬁrst-degree relatives (Riesel et al., 2011; Ullsperger et al., 2014)
The main limitation of the present study is the relatively small sam-
ple recruited. Although many individuals showed initial interest theywere discouraged by what they perceived as the pathologization of
their perceptual and cognitive experiences, and also by the use of an an-
tipsychotic in the study. Consequently, these resultsmust be considered
preliminary.
To sum up, individuals with SPD showed deﬁcits in self-monitoring
analogous to those in schizophrenia, highlighting a common
endophenotype in schizophrenia spectrum disorders. These deﬁcits
suggest a dopaminergic imbalance also in SPD, can be evidenced by
neurophysiological measures, and can be reverted by antipsychotic
medication. Future studies should attempt the assessment of neuro-
physiological measures of behavioral monitoring in larger SPD patient
samples.
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